BR112019000709A8 - Sistema para avaliar uma condição tratável com antibióticos em relação a um usuário e método para avaliar uma condição associada a antibióticos em relação a um primeiro usuário - Google Patents

Sistema para avaliar uma condição tratável com antibióticos em relação a um usuário e método para avaliar uma condição associada a antibióticos em relação a um primeiro usuário

Info

Publication number
BR112019000709A8
BR112019000709A8 BR112019000709A BR112019000709A BR112019000709A8 BR 112019000709 A8 BR112019000709 A8 BR 112019000709A8 BR 112019000709 A BR112019000709 A BR 112019000709A BR 112019000709 A BR112019000709 A BR 112019000709A BR 112019000709 A8 BR112019000709 A8 BR 112019000709A8
Authority
BR
Brazil
Prior art keywords
user
relation
antibiotics
condition
antibiotic
Prior art date
Application number
BR112019000709A
Other languages
English (en)
Other versions
BR112019000709A2 (pt
Inventor
Apte Zachary
Richman Jessica
Almonacid Daniel
Pedroso Inti
Ugalde Juan
Ortiz Rodrigo
Original Assignee
Ubiome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/606,743 external-priority patent/US10803991B2/en
Application filed by Ubiome Inc filed Critical Ubiome Inc
Publication of BR112019000709A2 publication Critical patent/BR112019000709A2/pt
Publication of BR112019000709A8 publication Critical patent/BR112019000709A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/74—Details of notification to user or communication with user or patient ; user input means
    • A61B5/746—Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/74—Details of notification to user or communication with user or patient ; user input means
    • A61B5/7465—Arrangements for interactive communication between patient and care services, e.g. by using a telephone network
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/13—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Nursing (AREA)
  • Physiology (AREA)
  • Artificial Intelligence (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)

Abstract

SISTEMA PARA AVALIAR UMA CONDIÇÃO TRATÁVEL COM ANTIBIÓTICOS EM RELAÇÃO A UM USUÁRIO E MÉTODO PARA AVALIAR UMA CONDIÇÃO ASSOCIADA A ANTIBIÓTICOS EM RELAÇÃO A UM PRIMEIRO USUÁRIO As realizações de um método e de um sistema para farmacogenômicos microbianos podem incluir: um sistema de manipulação de amostra operável para coletar recipientes incluindo amostras biológicas a partir de um conjunto de usuários, o sistema de manipulação incluindo um sistema de sequenciamento operável para determinar as sequências de microrganismos a partir de amostras biológicas; um sistema de caracterização de microbioma operável para: determinar dados de farmacogenômicos de microbioma baseados nas sequências de microrganismos, coletar dados suplementares associados com a condição associada aos antibióticos para o conjunto de usuários e transformar os dados suplementares e as características extraídas dos dados de farmacogenômicos de microbioma em um modelo de caracterização associado com a condição associada aos antibióticos; e um sistema de tratamento operável para promover um tratamento ao usuário para a condição associada aos antibióticos com base na caracterização do material biológico do usuário com o modelo de caracterização em relação à condição associada aos antibióticos.
BR112019000709A 2016-07-13 2017-07-13 Sistema para avaliar uma condição tratável com antibióticos em relação a um usuário e método para avaliar uma condição associada a antibióticos em relação a um primeiro usuário BR112019000709A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662361943P 2016-07-13 2016-07-13
US15/606,743 US10803991B2 (en) 2014-10-21 2017-05-26 Method and system for microbiome-derived diagnostics and therapeutics
PCT/US2017/042015 WO2018013865A1 (en) 2016-07-13 2017-07-13 Method and system for microbial pharmacogenomics

Publications (2)

Publication Number Publication Date
BR112019000709A2 BR112019000709A2 (pt) 2019-05-14
BR112019000709A8 true BR112019000709A8 (pt) 2023-03-21

Family

ID=60953350

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019000709A BR112019000709A8 (pt) 2016-07-13 2017-07-13 Sistema para avaliar uma condição tratável com antibióticos em relação a um usuário e método para avaliar uma condição associada a antibióticos em relação a um primeiro usuário

Country Status (12)

Country Link
EP (1) EP3484348A4 (pt)
JP (2) JP2019521706A (pt)
KR (1) KR102397683B1 (pt)
CN (1) CN109475305B (pt)
AU (1) AU2017295861A1 (pt)
BR (1) BR112019000709A8 (pt)
CA (1) CA3030792A1 (pt)
CO (1) CO2019001319A2 (pt)
EA (1) EA201990294A1 (pt)
SG (1) SG11201900253TA (pt)
WO (1) WO2018013865A1 (pt)
ZA (1) ZA201900473B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018378356B2 (en) * 2017-12-04 2023-09-14 Cybele Microbiome, Inc. Methods and compositions for identification and modulation of microbiome biochemical pathways to alter phenotype
WO2019178610A1 (en) * 2018-03-16 2019-09-19 uBiome, Inc. Method and system for characterization of metabolism-associated conditions, including diagnostics and therapies, based on bioinformatics approach
KR20200143462A (ko) 2018-04-13 2020-12-23 프리놈 홀딩스, 인크. 생물학적 샘플의 다중 분석물 검정을 위한 기계 학습 구현
EP3803901A1 (en) * 2018-06-07 2021-04-14 4D Pharma Plc Method for stratifying ibs patients
KR102346398B1 (ko) 2020-09-01 2022-01-03 주식회사 에이아이바이오틱스 장내 미생물을 분석하여 평가 하는 시스템 및 평가 방법
US20220367050A1 (en) * 2021-05-12 2022-11-17 Zoe Limited Predicting gut microbiome diversity

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017951A2 (en) * 1994-12-09 1996-06-13 Rpms Technology Limited Identification of genes responsible for in vivo survival of microorganisms
PL1631264T5 (pl) * 2003-06-02 2018-09-28 Glaxosmithkline Biologicals Sa Kompozycje immunogenne oparte na biodegradowalnych mikrocząstkach zawierających toksoid błonicy i tężca
US7955837B2 (en) * 2005-10-29 2011-06-07 Bayer Technology Services Gmbh Process for determining one or more analytes in samples of biological origin having complex composition, and use thereof
CN104031984A (zh) * 2008-02-28 2014-09-10 俄亥俄州立大学研究基金会 用于前列腺相关病症的诊断、预后和治疗的基于微rna的方法和组合物
CN102264899A (zh) * 2008-11-04 2011-11-30 血细胞保存公司 弯曲的玻璃表面上的核酸提取
WO2011093674A2 (ko) * 2010-01-29 2011-08-04 (주)유바이오메드 마이크로 니들 및 마이크로 니들장치
CA2792956C (en) * 2010-03-17 2021-11-16 Socpra - Sciences Et Genie, S.E.C. Bacterial vaccine components from staphylococcus aureus and uses thereof
CN101833613A (zh) * 2010-06-04 2010-09-15 中国科学院青岛生物能源与过程研究所 一种口腔微生物群落数据库及其应用
US20130121968A1 (en) * 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
US9719144B2 (en) * 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
US20140143188A1 (en) * 2012-11-16 2014-05-22 Genformatic, Llc Method of machine learning, employing bayesian latent class inference: combining multiple genomic feature detection algorithms to produce an integrated genomic feature set with specificity, sensitivity and accuracy
JP6479685B2 (ja) * 2013-02-04 2019-03-06 セレス セラピューティクス インコーポレイテッド 病原性細菌生育の抑制のための組成物および方法
KR20160009541A (ko) * 2013-03-15 2016-01-26 프로메데온 파마, 엘엘씨 화합물의 경피전달 장치, 시스템, 및 방법
US9466024B2 (en) * 2013-03-15 2016-10-11 Northrop Grumman Systems Corporation Learning health systems and methods
WO2015003000A1 (en) * 2013-07-01 2015-01-08 Counterpoint Health Solutions, Inc. Systems biology approach to therapy
US10633714B2 (en) * 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
WO2015066625A1 (en) * 2013-11-01 2015-05-07 Washington University Methods to establish and restore normal gut microbiota function of subject in need thereof
CA2936933C (en) * 2014-01-25 2024-05-21 uBiome, Inc. Method and system for microbiome analysis
EP3203911A4 (en) * 2014-10-09 2018-06-27 Luminacare Solutions Inc. Personalized antibiotic dosing platform
CA2962466C (en) * 2014-10-21 2023-01-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
BR112017011850A2 (pt) * 2014-12-05 2018-02-27 Univ Saskatchewan métodos e reagentes para detectar neisseria gonorrhoeae e seus determinantes de resistência antimicrobiana
CN105648060B (zh) * 2016-01-29 2020-01-31 江汉大学 一种非诊断目的的人体病原微生物耐药性基因的检测方法

Also Published As

Publication number Publication date
EA201990294A1 (ru) 2019-08-30
EP3484348A4 (en) 2021-11-24
CN109475305A (zh) 2019-03-15
JP2019521706A (ja) 2019-08-08
EP3484348A1 (en) 2019-05-22
WO2018013865A1 (en) 2018-01-18
BR112019000709A2 (pt) 2019-05-14
CA3030792A1 (en) 2018-01-18
AU2017295861A1 (en) 2019-01-24
SG11201900253TA (en) 2019-02-27
ZA201900473B (en) 2019-09-25
KR20190033561A (ko) 2019-03-29
KR102397683B1 (ko) 2022-05-13
CN109475305B (zh) 2022-01-25
JP2022079646A (ja) 2022-05-26
CO2019001319A2 (es) 2019-02-19

Similar Documents

Publication Publication Date Title
BR112019000709A8 (pt) Sistema para avaliar uma condição tratável com antibióticos em relação a um usuário e método para avaliar uma condição associada a antibióticos em relação a um primeiro usuário
Del Real et al. Differential analysis of genome-wide methylation and gene expression in mesenchymal stem cells of patients with fractures and osteoarthritis
BR112019005025A2 (pt) sistema e método para caracterizar um painel
WO2017172644A3 (en) Bacteria identification and antibiotic susceptibility profiling device
WO2015112352A8 (en) Method and system for microbiome analysis
WO2016015058A3 (en) Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
MX2016016902A (es) Metodos para analizar acidos nucleicos de celulas individuales o poblaciones de celulas.
MY198081A (en) Urinalysis device and dry reagent for quantitative urinalysis
BR112014000965B8 (pt) Método, aparelho e meio de armazenamento não transitório
WO2014170497A3 (en) Method for identifying the quantitative cellular composition in a biological sample
NZ600681A (en) Assay for jc virus antibodies
BR112019006879A2 (pt) sistema de análise e método para testagem de uma amostra
EP2977467A3 (en) Method, use of marker, and determination device for obtaining information on plural types of cancers
BR112018006393A2 (pt) método para classificar um linfoma difuso de grande célula b (dlbcl), uma ou mais mídias de armazenamento legíveis por computador, sistema de computação adaptado e kit
EP3009842A3 (en) Method for supporting diagnosis of risk of colorectal cancer recurrence, program and computer system
Martinez-Fernandez et al. Sample processing methods impacts on rumen microbiome
Fleming et al. New RNA methods for the identification of body fluids and cell types
WO2016051177A3 (en) Methods and kits
Wager et al. A fence barrier method of leading edge cell capture for explorative biochemical research
Leary et al. Sub-Cluster Identification through Semi-Supervised Optimization of Rare-cell Silhouettes (SCISSORS) in Single-Cell Sequencing
Abedi et al. Seroprevalence of Babesia caballi Infection in Horses in the North Khorasan Province of
GB2561319A (en) Screening and culture method
Selt et al. Establishment and application of a novel patient-derived KIAA1549
Menegidio et al. MATERIALS AND METHODS-FUNGAL DYSBIOSIS CORRELATES WITH THE DEVELOPMENT OF TUMOUR-INDUCED CACHEXIA IN MICE
Hernández-Garduño Comment on" nontuberculous mycobacteria isolation from clinical and environmental samples in Iran: twenty years of surveillance"

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61B 5/00 , A61K 35/74

Ipc: A61B 5/00 (2006.01), C12Q 1/689 (2018.01)

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements